2025-11-122025-11-122025TURONES, Larissa C. et al. Centrally acting chalcones: from anticancer and antinociceptive properties to molecular considerations. Current Pharmacology Reports, Berlin, v. 11, e1, 2025. DOI: 10.1007/s40495-024-00385-9. Disponível em: https://link.springer.com/article/10.1007/s40495-024-00385-9. Acesso em: 11 nov. 2025.e- 2198-641Xhttps://link.springer.com/article/10.1007/s40495-024-00385-9This review reveals multiple targets of chalcones and provides structure-to-activity relationships and the mechanism of actions of chalcones. Research data consistently provide anticancer and antinociceptive evidence for some chalcones. The physicochemical characterization and molecular modeling of cardamonin—CD (multitargeted nutraceutical) with anticancer and antinociceptive properties provide insight into its pharmacological profile. Active sites of CD that are favorable for electrophilic attacks could interfere with cell proliferation pathways or trigger programmed cell death. The ability of oxygen atoms from CD to donate electrons may favor interaction with specific sites on cancer cells before a potential inhibition of uncontrolled cell growth and elicit an antinociceptive effect and antioxidant reactions that decrease inflammation and pain perception. Further research on chemical modifications and significant structural motifs of the privileged chalcone scaffold could produce new chalcone derivatives with enriched pharmacology.engAcesso RestritoArtigo10.1007/s40495-024-00385-9